BACKGROUND: The HIV Prevention Trials Network (HPTN) 046 trial evaluated the efficacy of extended infant nevirapine (NVP) administration for prevention of HIV transmission through breastfeeding. Infants received daily NVP up to 6 weeks of age. HIV-uninfected infants (the intent-to-treat group) received daily NVP or placebo up to 6 months of age. We analyzed emergence of NVP resistance in infants who acquired HIV infection despite prophylaxis. METHODS: HIV genotyping was performed using the ViroSeq HIV Genotyping System. Medians and proportions were used to summarize data. Two-sided Fisher exact tests were used to evaluate associations between categorical variables. RESULTS:NVP resistance was detected in 12 (92.3%) of 13 infants who were HIV-infected by 6 weeks and in 7 (28%) of 25 infants who were HIV-uninfected at 6 weeks and HIV-infected at 6 months of age (6/8 = 75% in the NVP arm, 1/17 = 5.9% in the placebo arm, P = 0.001). Among those 25 infants, 4 had mothers who initiated an antiretroviral treatment regimen by 6 months postpartum. In all 4 cases, the treatment regimen included a non-nucleoside reverse transcriptase inhibitor (NVP or efavirenz). NVP resistance was detected in all 4 of those infants by 6 months of age (4/4 = 100%). In contrast, only 3 (14.2%) of the remaining 21 HIV-infected infants whose mothers did not initiate antiretroviral treatment developed NVP resistance (P = 0.003). CONCLUSIONS: Extended NVP prophylaxis significantly increased the risk of NVP resistance in infants who acquired HIV infection after 6 weeks of age. Treatment of maternal HIV infection was also associated with emergence of NVP resistance in HIV-infected, breastfed infants.
RCT Entities:
BACKGROUND: The HIV Prevention Trials Network (HPTN) 046 trial evaluated the efficacy of extended infantnevirapine (NVP) administration for prevention of HIV transmission through breastfeeding. Infants received daily NVP up to 6 weeks of age. HIV-uninfectedinfants (the intent-to-treat group) received daily NVP or placebo up to 6 months of age. We analyzed emergence of NVP resistance in infants who acquired HIV infection despite prophylaxis. METHODS: HIV genotyping was performed using the ViroSeq HIV Genotyping System. Medians and proportions were used to summarize data. Two-sided Fisher exact tests were used to evaluate associations between categorical variables. RESULTS: NVP resistance was detected in 12 (92.3%) of 13 infants who were HIV-infected by 6 weeks and in 7 (28%) of 25 infants who were HIV-uninfected at 6 weeks and HIV-infected at 6 months of age (6/8 = 75% in the NVP arm, 1/17 = 5.9% in the placebo arm, P = 0.001). Among those 25 infants, 4 had mothers who initiated an antiretroviral treatment regimen by 6 months postpartum. In all 4 cases, the treatment regimen included a non-nucleoside reverse transcriptase inhibitor (NVP or efavirenz). NVP resistance was detected in all 4 of those infants by 6 months of age (4/4 = 100%). In contrast, only 3 (14.2%) of the remaining 21 HIV-infectedinfants whose mothers did not initiate antiretroviral treatment developed NVP resistance (P = 0.003). CONCLUSIONS: Extended NVP prophylaxis significantly increased the risk of NVP resistance in infants who acquired HIV infection after 6 weeks of age. Treatment of maternal HIV infection was also associated with emergence of NVP resistance in HIV-infected, breastfed infants.
Authors: Susan H Eshleman; Laura A Guay; Anthony Mwatha; Elizabeth R Brown; Shawn P Cunningham; Philippa Musoke; Francis Mmiro; J Brooks Jackson Journal: J Acquir Immune Defic Syndr Date: 2004-02-01 Impact factor: 3.731
Authors: J A Coates; N Cammack; H J Jenkinson; A J Jowett; M I Jowett; B A Pearson; C R Penn; P L Rouse; K C Viner; J M Cameron Journal: Antimicrob Agents Chemother Date: 1992-04 Impact factor: 5.191
Authors: Jessica D Church; Saad B Omer; Laura A Guay; Wei Huang; Jessica Lidstrom; Philippa Musoke; Francis Mmiro; J Brooks Jackson; Susan H Eshleman Journal: J Infect Dis Date: 2008-10-01 Impact factor: 5.226
Authors: Newton I Kumwenda; Donald R Hoover; Lynne M Mofenson; Michael C Thigpen; George Kafulafula; Qing Li; Linda Mipando; Kondwani Nkanaunena; Tsedal Mebrahtu; Marc Bulterys; Mary Glenn Fowler; Taha E Taha Journal: N Engl J Med Date: 2008-06-04 Impact factor: 91.245
Authors: Elise Arrivé; Marie-Louise Newell; Didier K Ekouevi; Marie-Laure Chaix; Rodolphe Thiebaut; Bernard Masquelier; Valériane Leroy; Philippe Van de Perre; Christine Rouzioux; François Dabis Journal: Int J Epidemiol Date: 2007-05-28 Impact factor: 7.196
Authors: Julie A E Nelson; Ali Fokar; Michael G Hudgens; Kara J Compliment; Justin Tyler Hawkins; Gerald Tegha; Deborah D Kamwendo; Dumbani Kayira; Innocent A Mofolo; Athena P Kourtis; Denise J Jamieson; Charles M Van Der Horst; Susan A Fiscus Journal: AIDS Date: 2015-10-23 Impact factor: 4.177
Authors: Ceejay L Boyce; Tatiana Sils; Daisy Ko; Annie Wong-On-Wing; Ingrid A Beck; Sheila M Styrchak; Patricia DeMarrais; Camlin Tierney; Lynda Stranix-Chibanda; Patricia M Flynn; Taha E Taha; Maxensia Owor; Mary Glenn Fowler; Lisa M Frenkel Journal: Clin Infect Dis Date: 2022-06-10 Impact factor: 20.999
Authors: Iris Chen; Leila Khaki; Jane C Lindsey; Carrie Fry; Matthew M Cousins; Robert F Siliciano; Avy Violari; Paul Palumbo; Susan H Eshleman Journal: PLoS One Date: 2013-11-27 Impact factor: 3.240